Bellevue Life Sciences Acquisition Corp. (Nasdaq: BLAC) has signed a non-binding letter of intent (LOI) to combine with global healthcare holding company OSR Holdings, Ltd.
Seoul, South Korea-based OSR leverages its international network of partners in the US, Europe, and South Korea to develop and license its pipeline of innovative biomedical therapies based on proprietary platform technologies, with the ultimate goal of addressing unmet medical needs.
Although Bellevue did not provide much information on the potential transaction, it expects to finalize the definitive agreement within the coming weeks and will announce additional details at that time. With a November 14 completion deadline, the parties intend to complete the business combination in the fourth quarter of 2023.
Upon completion of the business combination, the surviving company will be renamed OSR Biosciences, Inc.
OSR Holdings currently wholly owns three operating subsidiaries in Switzerland and South Korea, two of which are focused on developing therapeutic drugs in the areas of oncology and osteoarthritis, and the third is a distributor of medical devices for the treatment of neurovascular and other diseases.
Additionally, OSR Holdings signed a separate LOI on July 7 to acquire Landmark BioVentures AG, a Swiss company that operates through four different biotech ventures in France with therapeutic focuses on oncology and immunology.
Bellevue Life Sciences priced its $60 million IPO earlier this year in February and initially set out to acquire a target business in the healthcare industry, specifically in the biotechnology sector developing the next generation of biologics. The SPAC is led by CEO Kuk Hyuon Hwang, CFO David J. Yoo, and Nominee for Chairman of the Board Steven Reed.
At the SPAC of Dawn SPACs celebrated the beginning of the Fed meeting today with two new deal announcements. Both transactions are by Asia-based teams, but represent seemingly very different processes. Horizon Space I (NASDAQ:HSPO) has been working on its combination with Squirrel Enlivened since at least last October, when it signed an letter of...
Many things go into an M&A transaction negotiation, but one of the most common points at issue in SPAC deals is the fate of the sponsor’s promote. While the two sides might wrangle back and forth on the target’s valuation and potential earnout consideration, it is also common for the sponsor to agree to concessions...
At the SPAC of Dawn The tantalizing “will they, won’t they” drama around rate cuts appears set to finally come to a head this week as the Federal Reserve is expected to make an interest rate decision Wednesday morning. But, that is far from all that is going down in SPACland this week. The five...
Terms Tracker for the Week Ending September 13, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. We were expecting this week to be busier than it was since it was the first 5-day week post-Summer. However, it was actually very light....
Alpha Star (NASDAQ:ALSA) has entered into a definitive agreement to combine with fintech firm XDATA at an equity value of $180 million. Tallinn, Estonia-based XData provides payment software and digital banking systems for business clients. The combined company is expected to trade on the Nasdaq once the deal is completed in late 2024. Transaction Overview...